Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.

Details

Serval ID
serval:BIB_10535
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.
Journal
International Journal of Cancer
Author(s)
Marchand M., van Baren N., Weynants P., Brichard V., Dréno B., Tessier M.H., Rankin E., Parmiani G., Arienti F., Humblet Y., Bourlond A., Vanwijck R., Liénard D., Beauduin M., Dietrich P.Y., Russo V., Kerger J., Masucci G., Jäger E., De Greve J., Atzpodien J., Brasseur F., Coulie P.G., van der Bruggen P., Boon T.
ISSN
0020-7136
Publication state
Published
Issued date
1999
Volume
80
Number
2
Pages
219-230
Language
english
Notes
Publication types: Clinical Trial ; Controlled Clinical Trial ; Journal Article
Abstract
Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease-free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE-3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.
Keywords
Adult, Aged, Antigen Presentation, Antigens, Neoplasm/adverse effects, Antigens, Neoplasm/genetics, Disease Progression, Female, Genetic Code, HLA-A1 Antigen/immunology, Humans, Immunotherapy, Male, Melanoma/secondary, Melanoma/therapy, Middle Aged, Neoplasm Proteins/adverse effects, Neoplasm Proteins/genetics, Remission Induction/methods
Pubmed
Web of science
Open Access
Yes
Create date
19/11/2007 12:00
Last modification date
20/08/2019 12:37
Usage data